These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 35006033)

  • 1. Nivolumab induced hypophysitis in an advanced RCC patient.
    Korkmaz Yilmaz M; Gulturk I; Tacar SY; Yilmaz M
    J Oncol Pharm Pract; 2022 Apr; 28(3):759-762. PubMed ID: 35006033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Magnetic resonance imaging criteria of immune checkpoint inhibitor-induced hypophysitis.
    Nada A; Bhat R; Cousins J
    Curr Probl Cancer; 2021 Feb; 45(1):100644. PubMed ID: 32888700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recovery from secondary adrenal insufficiency in a patient with immune checkpoint inhibitor therapy induced hypophysitis.
    Thapi S; Leiter A; Galsky M; Gallagher EJ
    J Immunother Cancer; 2019 Sep; 7(1):248. PubMed ID: 31511065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nivolumab-induced hypophysitis causing secondary adrenal insufficiency after transient ACTH elevation.
    Sekizaki T; Kameda H; Oba C; Yong Cho K; Nakamura A; Miyoshi H; Osawa T; Shinohara N; Atsumi T
    Endocr J; 2019 Oct; 66(10):937-941. PubMed ID: 31217401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autoimmune hypophysitis secondary to therapy with immune checkpoint inhibitors: Four cases describing the clinical heterogeneity of central endocrine dysfunction.
    Hartmann A; Paparoupa M; Volkmer BG; Rompel R; Wittig A; Schuppert F
    J Oncol Pharm Pract; 2020 Oct; 26(7):1774-1779. PubMed ID: 32164491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A Case of Metachronous Occurrence of Interstitial Pneumonitis and Hypophysitis Following Nivolumab Plus Ipilimumab for Metastatic Renal Cell Carcinoma].
    Hayase T; Washino S; Mayumi S; Yazaki K; Nakamura Y; Oshima M; Konishi T; Saito K; Miyagawa T
    Hinyokika Kiyo; 2021 Jun; 67(6):239-243. PubMed ID: 34265899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypophysitis secondary to nivolumab and pembrolizumab is a clinical entity distinct from ipilimumab-associated hypophysitis.
    Faje A; Reynolds K; Zubiri L; Lawrence D; Cohen JV; Sullivan RJ; Nachtigall L; Tritos N
    Eur J Endocrinol; 2019 Sep; 181(3):211-219. PubMed ID: 31176301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune checkpoint inhibitor-induced hypophysitis: lessons learnt from a large cancer cohort.
    Kotwal A; Rouleau SG; Dasari S; Kottschade L; Ryder M; Kudva YC; Markovic S; Erickson D
    J Investig Med; 2022 Apr; 70(4):939-946. PubMed ID: 34969937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nivolumab-induced hypophysitis followed by acute-onset type 1 diabetes with renal cell carcinoma: a case report.
    Kikuchi F; Saheki T; Imachi H; Kobayashi T; Fukunaga K; Ibata T; Sato S; Ban N; Lyu J; Japar S; Murao K
    J Med Case Rep; 2021 Apr; 15(1):214. PubMed ID: 33892782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The association of hypophysitis with immune checkpoint inhibitors use: Gaining insight through the FDA pharmacovigilance database.
    Tang Q; Han Y; Song M; Peng J; Zhang M; Ren X; Sun H
    Medicine (Baltimore); 2024 Mar; 103(13):e37587. PubMed ID: 38552079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nivolumab-induced hypophysitis in a patient with advanced malignant melanoma.
    Okano Y; Satoh T; Horiguchi K; Toyoda M; Osaki A; Matsumoto S; Tomaru T; Nakajima Y; Ishii S; Ozawa A; Shibusawa N; Shimada T; Higuchi T; Chikamatsu K; Yamada M
    Endocr J; 2016 Oct; 63(10):905-912. PubMed ID: 27440480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Checkpoint Inhibitor-Associated Hypophysitis.
    Chang LS; Yialamas MA
    J Gen Intern Med; 2018 Jan; 33(1):125-127. PubMed ID: 28770379
    [No Abstract]   [Full Text] [Related]  

  • 13. A Case of Metastatic Fumarate Hydratase-Deficient-like Renal Cell Carcinoma Successfully Managed by Ipilimumab plus Nivolumab.
    Sekito T; Takamoto A; Kobayashi Y; Mitsui M; Watari S; Kubota R; Sadahira T; Iwata T; Nishimura S; Edamura K; Sako T; Araki M; Watanabe M; Watanabe T; Shibata R; Ennishi D; Nasu Y
    Acta Med Okayama; 2021 Jun; 75(3):397-402. PubMed ID: 34176946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fulminant ACTH decrease following diabetic ketoacidosis induced by immune checkpoint inhibitor combination therapy with nivolumab and ipilimumab: A case report.
    Iesaka H; Kameda H; Miya A; Nomoto H; Cho KY; Nakamura A; Abe T; Shinohara N; Atsumi T
    Medicine (Baltimore); 2023 Dec; 102(51):e36664. PubMed ID: 38134115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myocarditis as an immune-related adverse event following treatment with ipilimumab and nivolumab combination therapy for metastatic renal cell carcinoma: a case report.
    Miyauchi Y; Naito H; Tsunemori H; Tani R; Hasui Y; Miyake Y; Minamino T; Ishikawa R; Kushida Y; Haba R; Sugimoto M
    J Med Case Rep; 2021 Oct; 15(1):508. PubMed ID: 34649593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic impact of immune-related adverse events in metastatic renal cell carcinoma treated with nivolumab plus ipilimumab.
    Ikeda T; Ishihara H; Nemoto Y; Tachibana H; Fukuda H; Yoshida K; Takagi T; Iizuka J; Hashimoto Y; Ishida H; Kondo T; Tanabe K
    Urol Oncol; 2021 Oct; 39(10):735.e9-735.e16. PubMed ID: 34172370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypophysitis induced by ipilimumab and nivolumab combination therapy for advanced renal cell carcinoma: A case report.
    Motonaga A; Nakanishi S; Tanaka K; Nishida S; Izumi K; Saito S
    Urol Case Rep; 2021 Sep; 38():101661. PubMed ID: 33868946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fatal fulminant hepatitis induced by combined ipilimumab and nivolumab therapy despite favorable histologic response and confirmed by autopsy in a patient with clear cell renal cell carcinoma.
    Kubo T; Sugawara T; Shinkawa T; Kurisu T; Kouzen N; Tanaka T; Fukuta F; Yamasaki K; Sugita S; Matsuo K; Morita R; Hirohashi Y; Tsukahara T; Kanaseki T; Hasegawa T; Masumori N; Torigoe T
    Immunol Med; 2021 Jun; 44(2):136-141. PubMed ID: 32634346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy-induced autoimmune hypophysitis.
    Valecha G; Pant M; Ibrahim U; Atallah JP
    J Oncol Pharm Pract; 2019 Jan; 25(1):217-220. PubMed ID: 28825378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Onset of fulminant type 1 diabetes mellitus following hypophysitis after discontinuation of combined immunotherapy. A case report.
    Boswell L; Casals G; Blanco J; Jiménez A; Aya F; de Hollanda A; Halperin I; Arance AM; Mora M; Hanzu FA
    J Diabetes Investig; 2021 Dec; 12(12):2263-2266. PubMed ID: 34048145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.